Value proposition

Ncardia believes that human stem cell (iPSCs) technologies will bring better therapies to patients faster.

Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development.

Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process of disease modeling and high-throughput screening to accelerate drug discovery.
We listen to our customer’s project plans, questions and challenges, and co-develop human iPSC-based solutions that fit their specifications.

Explore our website to learn more www.ncardia.com.


stem cells, ipsc, cardiomyocytes, neurons, drug discovery, drug development, cardiovascular safety, cardiovascular efficacy, neural safety, neural efficacy, CRO, fibroblast, astrocytes, electrophysiology, safety pharmacology, toxicology, assay development, contraction assays, custom cell lines, assay solutions, disease modeling, HTS, and CMO